Robotic-assisted hysterectomy for endometrial cancer in people with obesity

Ontario Health
Record ID 32018011340
English
Authors' objectives: Robotic-assisted surgery has been used in Ontario hospitals for over a decade, but there is no public funding for the robotic systems or the disposables required to perform robotic-assisted surgeries (“robotics disposables”). We conducted a health technology assessment of robotic-assisted hysterectomy (RH) for the treatment of endometrial cancer in people with obesity. Our assessment included an evaluation of the effectiveness, safety, and cost-effectiveness of RH, as well as the 5-year budget impact for the Ontario Ministry of Health of publicly funding RH. It also looked at the experiences, preferences, and values of people with endometrial cancer and obesity, as well as those of health care professionals who provide surgical treatment for endometrial cancer.
Authors' results and conclusions: Compared with LH, RH is associated with fewer conversions to OH in patients with endometrial cancer and obesity (i.e., those with a BMI ? 40 kg/m2). Rates of perioperative complications were similarly low for both LH and RH. The cost-effectiveness of RH for people with endometrial cancer and obesity is unknown. We estimate that the 5-year budget impact of publicly funding RH for people with endometrial cancer and obesity would be $1.14 million. People we spoke with who had lived experience of endometrial cancer and obesity reported favourably on their experiences with minimally invasive hysterectomy (either LH or RH) and emphasized the importance of the availability of safe surgical options for people with obesity. Gynecological surgeons perceived RH as a superior alternative to OH and LH for people with endometrial cancer and obesity.
Authors' recommendations: Ontario Health, based on guidance from the Ontario Health Technology Advisory Committee, recommends publicly funding robotic-assisted hysterectomy for endometrial cancer in people with obesity.
Authors' methods: We performed a systematic literature search of the clinical evidence to identify systematic reviews and randomized controlled trials relevant to our research question. We reported the risk of bias from the included systematic review. We assessed the quality of the body of evidence according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group criteria. We performed a systematic economic literature search. We also analyzed the 5-year budget impact of publicly funding RH (including total, partial, and radical procedures) for people with endometrial cancer and obesity in Ontario. To contextualize the potential value of RH for people with endometrial cancer and obesity, we spoke with people with lived experience of endometrial cancer and obesity who had undergone minimally invasive surgery (either laparoscopic hysterectomy [LH] or RH), and we spoke with gynecological cancer surgeons who perform hysterectomy.
Details
Project Status: Completed
Year Published: 2023
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
Pubmed ID: 38026449
MeSH Terms
  • Endometrial Neoplasms
  • Hysterectomy
  • Robotic Surgical Procedures
  • Obesity
  • Obesity, Morbid
  • Laparoscopy
Keywords
  • Endometrial Neoplasms; Hysterectomy; Laparoscopy; Robotic Surgical Procedures
Contact
Organisation Name: Ontario Health
Contact Address: 525 University Ave, Toronto, ON M5G 2L3
Contact Name: Nancy Sikich, Director Health Technology Assessment
Contact Email: oh-hqo_hta@ontariohealth.ca
Copyright: The copyright for all Ontario Health publications is owned by the King’s Printer for Ontario. Materials may be reproduced for commercial purposes only under a licence from the King’s Printer. For further information or to request a licence to reproduce content, please contact: Senior Copyright Advisor Publications Ontario | 416-326-5153 | Copyright@Ontario.ca
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.